

**Supplementary Table S2. Summary of the results of compendial assay analysis**

No.	Active pharmaceutical ingredient (API)	Dosage form	Total number of samples	Falsified, not containing the declared API	API detected, but <50% of declared amount	API content from 50% to <80% of declared amount	API content ≥80% but lower than USP threshold	API content higher than USP threshold	API content within USP specifications
1	Atenolol	tablet	14	0	0	1	0	0	13
2	Ceftriaxone	powder for injection	23	0	0	0	0	0	23
3	Cefuroxime axetil	tablet	24	0	0	0	2	0	22
4	Chloroquine	tablet	16	1	1	0	1	1	12
5	Ciprofloxacin	tablet	26	0	0	0	5	0	21
6	Dexamethasone	tablet	22	0	1	7	12	0	2
7	Fluconazole	capsule or tablet	22	0	0	1	0	0	21
8	Furosemide	tablet	14	0	0	0	0	0	14
9	Glibenclamide	tablet	19	0	0	1	3	0	15
10	Hydrochlorothiazide	tablet	16	0	0	0	1	0	15
11	Metformin hydrochloride	tablet	22	0	0	0	1	0	21
12	Metronidazole	tablet	25	0	1	0	1	0	23
13	Cotrimoxazole	tablet	17	3	2	2	0	0	10
	<b>Total</b>		<b>260</b>	<b>4</b>	<b>5</b>	<b>12</b>	<b>26</b>	<b>1</b>	<b>212</b>

Detailed compendial analysis results of all samples are published in Gabel et al. (2024) Am J Trop Med Hyg 111: 179-195.